logo-loader

Allon Therapeutics

Receive alerts
Market:
TSX
Market Cap:
$201.61 m
Price
1.94 CAD
Change
0.00%
52 weeks high
2.04
52 weeks low
1.05

In brief

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Allon’s drug, davunetide, has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer’s disease, and in cognitive impairment associated with schizophrenia. Allon has advanced clinical development programs pursuing large underserved markets, such as Alzheimer's disease and CIAS and in orphan markets, such as frontotemporal dementias.